INVA Stock Analysis: Buy, Sell, or Hold?
INVA - Innoviva, Inc. Common Stock
$21.74
-0.47 (-2.12%)
▼
5d:
-2.29%
30d:
-3.12%
90d:
-9.3%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
20d
Get Alerted When INVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: INVA shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: INVA shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.63
Based on 9.9% avg growth
INTRINSIC VALUE TODAY
$22.75
4.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INVA is currently trading at $21.74, which is considered fair relative to its 30-day fair value range of $21.93 to $23.08. The stock's valuation (Forward PE: 9.8) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This pessimistic expectation contrasts with the company's recent 590.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INVA is in a downtrend. The price is currently testing key support at $21.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.50 (+63.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INVA is in a downtrend. The price is currently testing key support at $21.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.50 (+63.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$21.93 -
$23.08
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.3% below Wall St target ($35.50)
Trading Range Analysis
30-Day Trading Range
$21.93 -
$23.08
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$21.70
Resistance Level
$23.22
Current Trend
Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.84
Wall Street Target
$35.50
(+63.3%)
Revenue Growth (YoY)
10.6%
Earnings Growth (YoY)
590.4%
Profit Margin
119.9%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
9.8 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$21.35
(-2%)
2-Year Target
$20.96
(-4%)
3-Year Target
$20.59
(-5%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$21.77
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 15.7%)
$74.56
(+243%)
Base:
(SPY PE: 9.8, Growth: 15.7%)
$33.68
(+55%)
Bear:
(PE: 8.4, Growth: 15.7%)
$28.63
(+32%)
📈
Valuation based on Current Earnings
Trailing PE: 3.55 | Current EPS (TTM): $6.26
Bull Case
$12.23
(-44%)
Analyst growth -50.0%, PE expands to 3.9
Base Case
$11.12
(-49%)
Market implied -50.0%, PE stable at 3.6
Bear Case
$15.12
(-30%)
Severe decline -20.0%, PE contracts to 3.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 10.4
Stabilization Target:
$22.98
(+5.7%)
PE Expansion Potential:
+5.7%
Share & Embed Analysis
Last updated: July 14, 2026 10:11 PM ET
Data refreshes hourly during market hours. Next update: 11:11 PM
Data refreshes hourly during market hours. Next update: 11:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
Advanced INVA Option Strategies
Professional options setups generated by AI based on today's INVA price and gamma walls.
